The company applied AI to all Linq ICM devices in the U.S., Australia and New Zealand. It expects to roll it out in Europe later this year as well.
Reveal Linq helps detect arrhythmias and has been available around the world since 2014. Now, providers can access the AccuRhythm AI algorithms that reduce false alerts and improve information accuracy.
AccuRhythm AI applies deep learning algorithms flowing into the CareLink network to remove false AFib and false pause episodes. Medtronic developed the platform and initial algorithms using a database of more than 1 million electrocardiogram heart rhythm episodes. It’s applied automatically in the cloud with no required action from patients.
The FDA cleared the AccuRhythm algorithms for Linq II in 2021, then approved the AI for Reveal Linq last year.
Medtronic expects the addition of the algorithms to cumulatively reduce false AFib and pause alerts by 85%. Additionally, it projects the preservation of true alerts at a rate of 98.2% (AFib) and 99.9% (pause). The company said in a news release that this saves clinics more than 186 hours of false alert review per year for every 200 Reveal Linq patients. That gives clinicians more time to focus on more critical patient care activities.
“This milestone is both a nod to the past as we celebrate the thousands of patients who have benefited from Reveal LINQ over the last decade, and a glimpse into the future as an example of how AI can effectively update an established technology overnight,” said Stacey Churchwell, VP and GM, Cardiovascular Diagnostics and Services at Medtronic.
